EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure

Arancha Martí-Martínez iD, Julio Núñez iD, Herminio López-Escribano, Rafael de la Espriella, Enrique Santas, Enrique Rodriguez-Borja iD, Òscar Miró, Pere Llorens, Aitor Alquézar-Arbé, Pablo Herrero-Puente iD

Biomolecules · 2026

DOI: 10.3390/biom16091362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Arancha Martí-Martínez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Biochemistry Department, Valencia Clinical Hospital, 46010 Valencia, Spain. Hauptthemen laut MEDLINE: Heart Failure, Fibroblast Growth Factors. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro de Investigación Biomédica en Red, INCLIVA Health Research Institute, Institute of Health Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Worsening heart failure (WHF) is a complex clinical syndrome associated with a high risk of mortality and further decompensations, characterized by fluid overload and upregulated inflammatory and fibrotic processes linked to organ dysfunction. Fibroblast growth factor 23 (FGF23) is an emerging proxy of fibrosis and may interact to influence long-term outcomes in WHF patients. This study evaluated the association between FGF23 levels and long-term outcomes in patients with WHF evaluated in the emergency department (ED). A total of 635 patients from the EAHFE registry, enrolled during 2007, 2009, and 2011, were prospectively included. FGF23 was measured in the first blood sample obtained at ED presentation. During a median follow-up of 380 days (interquartile range: 126 to 456), all-cause mortality occurred in 216 patients (34.0%), while 351 patients (55.3%) experienced the composite endpoint of death/WHF ED reconsultation and 295 (46.5%) experienced death/HF hospitalization. Event rates increased progressively across FGF23 levels. Patients with FGF23 above the median (48.4 pg/mL) displayed higher rates (per 100 patient-years) of all-cause mortality (49 vs. 31, p = 0.003), death/WHF ED reconsultation (93 vs. 65, p = 0.003), and death/HF hospitalization (77 vs. 56, p = 0.043). In continuous analyses, each doubling of FGF23 remained significantly associated with an increased risk of all three outcomes after multivariable adjustment. These associations were consistent across clinically relevant subgroups, including those defined by age, sex, and kidney function, supporting the potential prognostic value of FGF23 within this cohort, although external validation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureFibroblast Growth FactorsHumansFibroblast Growth Factor-23FemaleMaleAgedMiddle AgedPrognosisAcute DiseaseProspective StudiesHospitalization

Stichwörter der Autor:innen

fibroblast growth factor 23fibrosisinflammationworsening heart failure

Substanzen

Fibroblast Growth Factor-23Fibroblast Growth FactorsFGF23 protein, human

Autor:innen und Institutionen

  • Clinical Biochemistry Department, Valencia Clinical Hospital, 46010 Valencia, Spain.
  • Cardiology Department, Valencia Clinical Hospital, Instituto de Investigación Sanitaria (INCLIVA), 46010 Valencia, Spain.
  • Emergency Department, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.
  • Emergency Department, Short Stay Unit and Hospital at Home, Hospital General Dr. Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), University of Alicante, 03010 Alicante, Spain.
  • Emergency Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Emergency Department, Asturias Central University Hospital, 33011 Oviedo, Spain.

ORCID-Profile: Arancha Martí-Martínez, Julio Núñez, Enrique Rodriguez-Borja, Pablo Herrero-Puente

Förderung

  • Centro de Investigación Biomédica en Red
  • INCLIVA Health Research Institute
  • Institute of Health Carlos III
  • Sociedad Española de Cardiología
  • Fondo Europeo de Desarrollo Regional
  • CIBER Cardiovascular
  • Unidad de Investigación Clínica y Ensayos Clínicos INCLIVA Health Research Institute, Spanish Clinical Research Network
  • Fondo Europeo de Desarrollo Regional—Instituto de Salud Carlos III

Zitieren

APA

Martí-Martínez, A., Núñez, J., López-Escribano, H., Espriella, R., Santas, E., Rodriguez-Borja, E., Miró, Ò., Llorens, P., Alquézar-Arbé, A., & Herrero-Puente, P. (2026). Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure. Biomolecules. https://doi.org/10.3390/biom16091362

Vancouver

Martí-Martínez A, Núñez J, López-Escribano H, Espriella R, Santas E, Rodriguez-Borja E, et al. Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure. Biomolecules. 2026. doi:10.3390/biom16091362

BibTeX
@article{MartMartnez2026,
  author = {Martí-Martínez, Arancha and Núñez, Julio and López-Escribano, Herminio and Espriella, Rafael de la and Santas, Enrique and Rodriguez-Borja, Enrique and Miró, Òscar and Llorens, Pere and Alquézar-Arbé, Aitor and Herrero-Puente, Pablo},
  title = {Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16091362}
}
Kostenlos starten →